Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [scRNA-Seq]

ABSTRACT: Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [scRNA-Seq]

PROVIDER: PRJNA976061 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24724651.fastq.gz	Fastqsanger.gz
	SRR24724652.fastq.gz	Fastqsanger.gz
	SRR24724653.fastq.gz	Fastqsanger.gz
	SRR24724654.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies

Project description:Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies

| PRJNA975812 | ENA

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [RNA-Seq]

Project description:Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [RNA-Seq]

| PRJNA975578 | ENA

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [RNA-Seq]

Project description:Graphene Oxide Antigen Presenting Platform was designed for human T cell activation superior to commercial beads. We used deep RNA sequencing to study the mechanism of the T cell activation from PBMCs.

2024-07-01 | GSE233259 | GEO

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies [scRNA-Seq]

Project description:Graphene Oxide Antigen Presenting Platform was designed for human T cell activation superior to commercial beads. We used single cell RNA sequencing (scRNA-seq) to study the genome-wide transcriptome profiling of the activated T cells from PBMCs.

2024-07-01 | GSE233290 | GEO

Biomimetic Cell Stimulation with Graphene Oxide Antigen Presenting Platform (GO-APP) for Developing T Cell-Based Therapies

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-07-01 | GSE233291 | GEO

A transcriptomic overview of lung and liver changes one day after pulmonary exposure to graphene and graphene oxide

Project description:This study investigates transcriptomic differences in the lung and liver after pulmonary exposure to two Graphene based materials with similar physical properties, but different surface chemistry. Female C57BL/6 mouse were exposed by a single intratracheal instillation of 0, 18, 54 or 162 μg/mouse of graphene oxide (GO) or reduced graphene oxide (rGO). Pulmonary and hepatic transcriptional changes were compared to identify commonly and uniquely perturbed functions and pathways by GO and rGO. These changes were then related to previously analyzed endpoints. GO exposure induced more differentially expressed genes, affected more functions, and perturbed more pathways compared to rGO, both in the lung and liver.

2020-10-21 | GSE159707 | GEO

Single-cell mass cytometry reveals the impact of graphene nanomaterials with human primary immune cells

Project description:The genome-wide transcriptome analysis highlight the increased biocompatibility on immune cells of graphene functionalized with amino groups (NH2) compared with graphene oxide (GO); reducing the cell metabolism disfunction. Moreover, GONH2 was found to polarizes T-cell and monocyte activation toward a T helper-1/M1 immune response.

2017-08-13 | GSE99929 | GEO

RNAseq of primary human monocyte derived macrophages (MDM) and differentiated THP-1 macrophages exposed to graphene-related (nano)materials (GRMs)

Project description:Occupational and consumer exposure to GRMs will increase but their impact on human health is still largely unknown. We sought to perform a transcriptome comparison of the bioresponses of MDM and THP-1 macrophages exposed to 5 or 20 µg/ml graphene oxide (GO) or graphene nanoplatelets (GNP) for 6 and 24 h to capture early and more persistent acute responses. Cristalline silica (DQ) was included as immunotoxic reference material.

2023-02-01 | E-MTAB-10099 | biostudies-arrayexpress

Graphene Oxide Substrate Promotes Neurotrophic Factor Secretion and Survival of Human Schwann-Like Adipose Mesenchymal Stromal Cells - RNAseq

Project description:Mesenchymal stromal cells from adipose tissue (AD-MSCs) exhibit favourable clinical traits for autologous transplantation and can develop a ‘Schwann-like’ phenotype (sAD-MSCs) to improve peripheral nerve regeneration, where severe injuries yield insufficient recovery. However, sAD-MSCs regress without biochemical stimulation and detach from conduits under unfavourable transplant conditions, negating their paracrine effects. Graphene-derived materials support AD-MSC attachment, regulating cell adhesion and function through physiochemistry and topography. We report graphene oxide (GO) as a suitable substrate for human sAD-MSCs incubation towards severe peripheral nerve injuries, through evaluating transcriptome changes, neurotrophic factor expression over a 7-day period, and cell viability in apoptotic conditions. Transcriptome changes from GO incubation across four patients were minor compared to biological variance.

2021-03-08 | E-MTAB-10078 | biostudies-arrayexpress

RNA-seq data of nasopharyngeal carcinoma (NPC) cell and GO-PEG_erlotinib treatment

Project description:graphene oxide (GO) is found to be a promising novel anti-cancer drug carrier. Erlotinib, a tyrosine kinase inhibitor (TKI) acting on the epidermal growth factor receptor (EGFR), has been proved for locally advanced or metastatic non-small cell lung cancer (NSCLC) and in combination with gemcitabine for locally advanced or metastatic pancreatic cancer in 2004, but its study in nasopharyngeal carcinoma (NPC) is still limited. We designed functionalized GO, polyethylene glycol-coated GO (GO-PEG), as drug carriers, which was loaded with erlotinib and showed promising anticancer effect on NPC cells. Our results showed that GO-PEG-erlotinib effectively suppressed NPC cell proliferation, migration, and invasion, likely by several mechanisms. GO-PEG-erlotinib may be the potential therapeutic agents for treating NPC in the future.

2021-12-27 | GSE151195 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data